Skip to content
Open access

Post-registration experience with divosilimab in patients with secondary progressive multiple sclerosis with recurrence

Sep 2026 · Meditsinskiy sovet = Medical Council · 0 citations · 13 references

Abstract

Introduction . Therapy aimed at eliminating CD20-positive B cells is considered one of the most significant advances in the treatment of multiple sclerosis. Divozilimab is a humanized anti-CD20 monoclonal antibody lacking fucose in its Fc fragment, which enhances its effector properties. Aim . Тo analyze the efficacy and tolerability of divozilimab in patients with secondary progressive multiple sclerosis with exacerbations in real-world clinical practice. Materials and methods . The prospective observational study included 20 patients with secondary progressive multiple sclerosis with exacerbations (55% women, median age 53.5 years) who received divozilimab for 12–24 months. The annualized relapse rate, MRI activity (T1 gadolinium-enhancing lesions, new T2 lesions), EDSS dynamics, the proportion of patients achieving NEDA-3, safety profile, and lymphocyte levels were assessed. Results . Over 12 months, the annualized relapse rate decreased from 0.9 to 0.05 (p < 0.01); the proportion of relapse-free patients increased from 10% to 90%. At 12 months, 95% of patients had no gadolinium-enhancing lesions. The median EDSS remained stable at 4.0 points, with a tendency to decrease to 3.5 points at 24 months. NEDA-3 was achieved in 85% of patients. Infusion reactions were observed in 25% of patients (mostly mild, during the first administration). No serious adverse events were reported. Conclusion. Divozilimab demonstrates pronounced suppression of inflammatory activity and a favorable safety profile in patients with secondary progressive multiple sclerosis with exacerbations, justifying its use in this clinical population.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.